Candriam S.C.A. Zymeworks Inc. Transaction History

Candriam S.C.A.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 09, 2021	SELL	$27.35 - $37.28 $12.9 Million - $17.6 Million	-473,124 Closed	0 $0
Q2 2021 Jul 20, 2021	BUY	$26.5 - $38.23 $2.96 Million - $4.27 Million	111,583 Added 30.86%	473,124 $16.4 Million
Q1 2021 Apr 29, 2021	BUY	$29.83 - $56.81 $59 - $113	2 Added 0.0%	361,541 $16.4 Million
Q4 2020 Jan 22, 2021	SELL	$39.12 - $54.99 $10.2 Million - $14.3 Million	-260,521 Reduced 41.88%	361,539 $17.1 Million
Q3 2020 Oct 19, 2020	BUY	$29.21 - $46.58 $8.11 Million - $12.9 Million	277,576 Added 80.58%	622,060 $29 Million
Q2 2020 Jul 23, 2020	BUY	$33.67 - $40.0 $3.78 Million - $4.49 Million	112,215 Added 48.31%	344,484 $12.4 Million
Q1 2020 May 26, 2020	BUY	$24.28 - $49.8 $339 - $697	14 Added 0.01%	232,269 $10.3 Million
Q4 2019 Jan 21, 2020	BUY	$24.84 - $45.46 $5.77 Million - $10.6 Million	232,255 New	232,255 $11,000

296K

Ticker ZYME
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,694,400
Market Cap $1B
Description
Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas...

Get notified when there are updates to the investment portfolio of Candriam S.C.A., based on Form 13F filings with the SEC.

Stay updated on Candriam S.C.A. with notifications on news.